Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TSC1 |
Variant | R424fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TSC1 R424fs results in a change in the amino acid sequence of the Tsc1 protein beginning at aa 424 of 1164, likely resulting in premature truncation of the functional protein (UniProt.org). R424fs has not been characterized however, due to the effects of other truncation mutations downstream of R424 (PMID: 11875047, PMID: 20547222), is predicted to lead to a loss of Tsc1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TSC1 mutant TSC1 inact mut TSC1 R424fs |
Transcript | NM_000368.5 |
gDNA | chr9:g.(132907364_132907365) |
cDNA | c.(1270_1269) |
Protein | p.R424fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006717271 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_011518979.3 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_011518979 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406596.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406594.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_000368.4 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_017015097 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_005272211 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406592.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_017015097.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406606.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_017015096 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406607.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_005272211.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_000368 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406595.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406602.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_000368.5 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406593.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_011518979.2 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_017015096.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
XM_006717271.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406601.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
NM_001406605.1 | chr9:g.(132907364_132907365) | c.(1270_1269) | p.R424fs | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TSC1 R424fs | transitional cell carcinoma | no benefit | Buparlisib | Case Reports/Case Series | Actionable | In a Phase II trial, Buparlisib (BKM120) treatment resulted in progressive disease in a patient with metastatic urothelial carcinoma harboring TSC1 R424fs (PMID: 32767682; NCT01551030). | 32767682 |